Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast Inc (MED) provides investors and stakeholders with centralized access to official company announcements and market-moving developments. This resource aggregates all press releases, financial disclosures, and strategic updates from the clinical nutrition leader known for its OPTAVIA® coaching programs and evidence-based weight management solutions.
Users will find chronological updates covering earnings reports, product innovations, leadership changes, and operational milestones. The curated collection serves as both historical record and strategic tool for tracking MED's position in the $250B+ global wellness industry.
Key content categories include quarterly financial results, clinical study publications, partnership announcements, and regulatory filings. All materials are sourced directly from Medifast's investor relations team to ensure accuracy and timeliness.
Bookmark this page for streamlined monitoring of MED's business trajectory, with updates organized to highlight material developments affecting long-term growth in the health solutions sector.
Medifast (NYSE: MED) will report its financial results for Q1 2023, which ended on March 31, on May 1, 2023, after the market closes. This announcement will be followed by a conference call at 4:30 PM ET the same day, featuring Dan Chard, CEO, and Jim Maloney, CFO. The call will be accessible via the Investor Relations section of Medifast's website and archived until August 1, 2023. Medifast is a leader in the U.S. weight management industry, generating around $7 billion in revenue and known for its OPTAVIA brand that promotes healthy habits. The company has received recognition as one of America’s Best Mid-Sized Companies and has positively impacted over 2 million lives through its health and wellness community.
Medifast (NYSE: MED) has declared a $1.65 quarterly cash dividend to its shareholders, payable on May 9, 2023, to those on record by March 28, 2023. This signifies the company's commitment to returning value to its investors. Medifast aims to maintain a program of quarterly dividends; however, future declarations are subject to the discretion of the Board, depending on various factors. As a leading player in the $7 billion U.S. weight management industry, Medifast's community-focused model has transformed over 2 million lives through OPTA VIA Coaches. For further details, visit MedifastInc.com.
Medifast (NYSE: MED) announced the appointment of Steven Zenker as its new Vice President of Investor Relations on March 2, 2023. Zenker brings over 30 years of experience in investor relations, financial planning, and investment management. Reporting to CFO Jim Maloney, he will enhance Medifast's investor relations strategy. Maloney expressed confidence in Zenker's leadership to strengthen connections with the financial community and communicate the company's unique business model. Zenker previously held various leadership roles, including at Sinclair Broadcast Group and Central Garden & Pet Company, and holds degrees from SUNY Albany and Fordham University.
Medifast (NYSE: MED) reported its fourth quarter 2022 results, revealing a revenue of $337.2 million, a decrease of 10.7% year-over-year. The company had 60,900 active OPTAVIA Coaches, with revenue per coach declining 12.4% to $5,538. Net income stood at $26.5 million, with an EPS of $2.41. For the full year, revenue increased 4.8% to $1.6 billion, but net income fell to $143.6 million. The company holds $87.7 million in cash and has no debt. Looking ahead, Q1 2023 revenue is projected between $300 million and $320 million.
FAQ
What is the current stock price of Medifast (MED)?
What is the market cap of Medifast (MED)?
